BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) CEO Sells $979,064.00 in Stock

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 3,680 shares of the firm's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $266.05, for a total value of $979,064.00. Following the completion of the sale, the chief executive officer now directly owns 1,460 shares of the company's stock, valued at $388,433. The trade was a 71.60% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

John Oyler also recently made the following trade(s):

• On Tuesday, June 17th, John Oyler sold 1,460 shares of BeOne Medicines stock. The stock was sold at an average price of $256.49, for a total value of $374,475.40.
• On Friday, June 6th, John Oyler sold 5,127 shares of BeOne Medicines stock. The stock was sold at an average price of $252.77, for a total value of $1,295,951.79.

BeOne Medicines Trading Down 2.3%

ONC traded down $5.70 during midday trading on Friday, hitting $247.08. 230,772 shares of the company were exchanged, compared to its average volume of 298,435. The business has a 50 day moving average of $245.59. The stock has a market cap of $27.07 billion, a price-to-earnings ratio of -66.42 and a beta of 0.30. The company has a quick ratio of 1.71, a current ratio of 1.96 and a debt-to-equity ratio of 0.05. BeOne Medicines Ltd. - Sponsored ADR has a 1-year low of $141.31 and a 1-year high of $287.88.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of ($0.71) by $1.93. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.12 billion. BeOne Medicines had a negative return on equity of 7.55% and a negative net margin of 9.40%. On average, equities analysts anticipate that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ONC. Royal Bank Of Canada reduced their target price on BeOne Medicines from $312.00 to $311.00 and set an "outperform" rating for the company in a research note on Thursday, May 8th. Wall Street Zen upgraded BeOne Medicines from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. JPMorgan Chase & Co. raised their target price on BeOne Medicines from $311.00 to $317.00 and gave the stock an "overweight" rating in a research note on Monday, April 21st. TD Securities restated a "buy" rating and issued a $334.00 target price on shares of BeOne Medicines in a research note on Thursday, April 24th. Finally, Sanford C. Bernstein set a $259.00 target price on BeOne Medicines in a research note on Thursday, March 13th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $319.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.